A scalable platform for EPSC-Induced MSC extracellular vesicles with therapeutic potential

Area of Science:

• Biotechnology
• Regenerative Medicine
• Stem Cell Biology

Background:

• Mesenchymal stem cell-derived extracellular vesicles (EVs) are promising for regenerative medicine and drug delivery.
• Clinical applications are hindered by donor variability, low scalability, and inconsistent quality.
• A standardized, robust production platform is crucial for therapeutic EVs.

Purpose of the Study:

• To develop a scalable biomanufacturing strategy for producing high-quality mesenchymal stem cell-derived extracellular vesicles (EVs).
• To establish a standardized platform for therapeutic EV production suitable for clinical translation.

Main Methods:

• Generated and expanded induced mesenchymal stem cells (iMSCs) from extended pluripotent stem cells (EPSCs) in suspension bioreactors.
• Utilized a fixed-bed bioreactor for automated, continuous iMSC expansion and EV harvesting.
• Isolated and characterized iMSC-derived EVs (iMSC-EVs) for size, morphology, markers, and bioactivity.
• Assessed therapeutic efficacy in a bleomycin-induced pulmonary fibrosis mouse model.

Main Results:

• iMSC-EVs demonstrated comparable characteristics to primary MSC-EVs (size, morphology, canonical markers).
• Bioreactor systems enabled large-scale iMSC expansion (>5x10⁸ cells/batch) and high EV production (~1.2x10¹³ particles/day).
• In vivo studies showed iMSC-EVs significantly reduced lung fibrosis and inflammation, comparable to primary MSC-EVs.

Conclusions:

• Established a scalable and standardized bioreactor-based platform for producing high-quality iMSC-EVs.
• Addressed key limitations in traditional EV production, enabling consistent therapeutic quality.
• Paved the way for AI-integrated, automated, GMP-compliant manufacturing of therapeutic EVs for clinical translation.